Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

India Expected To Get Next Set Of U.S. FDA Permanent Staff

This article was originally published in PharmAsia News

Executive Summary

India is likely to be next on the list of U.S. FDA plans to station inspectors in other countries as a follow-up to a similar step earlier in March in China. The agency said it would have eight full-time positions in China to monitor medicines intended for export to the United States, and plans to locate personnel in Europe, India, South America and West Asia. India is expected to be next to receive U.S. FDA inspectors since it has the largest number of FDA-approved drug plants outside the United States. (Click here for more

You may also be interested in...



Allogene Takes Step Closer To Off-The-Shelf CAR-Ts

Phase I data presented at ASCO for ALLO-501 offer proof of concept for the CD19 allogeneic CAR-T and a companion drug, ALLO-647, for lymphodepletion. 

Coronavirus Notebook: BARDA Contracting Scrutiny; Part D Cost Sharing

Dispatches from a world turned upside down covering a possible US government investigation into BARDA contracting practices and Medicare Part D plans waiving cost sharing for COVID-19 treatments.

New Testing Prompts New Finding Of NDMA, Cancer Risk In Metformin Products

The US FDA requests several manufacturers recall extended-release metformin based on studies confirming a higher NDMA impurity threshhold; previous testing found no significant risks. 

UsernamePublicRestriction

Register

SC142222

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel